Dyax proposes follow-on

Dyax Corp. (NASDAQ:DYAX) proposed a follow-on late Tuesday underwritten by Jefferies; Cowen; Leerink; and Needham. Dyax, which markets hereditary angioedema (HAE) drug Kalbitor ecallantide in the U.S....